Cargando…

Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas

Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years af...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaudio, Francesco, Giordano, Annamaria, Pavone, Vincenzo, Perrone, Tommasina, Curci, Paola, Pastore, Domenico, Delia, Mario, de' Risi, Clara, Spina, Alessandro, Liso, Vincenzo, Specchia, Giorgina
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023035/
https://www.ncbi.nlm.nih.gov/pubmed/21253449
http://dx.doi.org/10.1155/2011/707542
_version_ 1782196629098463232
author Gaudio, Francesco
Giordano, Annamaria
Pavone, Vincenzo
Perrone, Tommasina
Curci, Paola
Pastore, Domenico
Delia, Mario
de' Risi, Clara
Spina, Alessandro
Liso, Vincenzo
Specchia, Giorgina
author_facet Gaudio, Francesco
Giordano, Annamaria
Pavone, Vincenzo
Perrone, Tommasina
Curci, Paola
Pastore, Domenico
Delia, Mario
de' Risi, Clara
Spina, Alessandro
Liso, Vincenzo
Specchia, Giorgina
author_sort Gaudio, Francesco
collection PubMed
description Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years after the achievement of first complete remission. Of 532 consecutive pts with classical HL treated at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission. Relapse occurred in 151 pts: 135 (29.8%) within 5 years and 16 over 5 years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7 years (range: 5–18). Salvage treatment induced complete remission in 14 pts (87.5%). At a median of 4 years after therapy for very late relapse, 10 pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at 5 years was 75%. The majority of deaths are due to treatment-related complications. Therapy regimens for very late relapse HL are warranted to minimize complications.
format Text
id pubmed-3023035
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30230352011-01-20 Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas Gaudio, Francesco Giordano, Annamaria Pavone, Vincenzo Perrone, Tommasina Curci, Paola Pastore, Domenico Delia, Mario de' Risi, Clara Spina, Alessandro Liso, Vincenzo Specchia, Giorgina Adv Hematol Clinical Study Recurrences of Hodgkin's Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, defined as relapses that occurred 5 or more years after the achievement of first complete remission. Of 532 consecutive pts with classical HL treated at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission. Relapse occurred in 151 pts: 135 (29.8%) within 5 years and 16 over 5 years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7 years (range: 5–18). Salvage treatment induced complete remission in 14 pts (87.5%). At a median of 4 years after therapy for very late relapse, 10 pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at 5 years was 75%. The majority of deaths are due to treatment-related complications. Therapy regimens for very late relapse HL are warranted to minimize complications. Hindawi Publishing Corporation 2011 2010-12-29 /pmc/articles/PMC3023035/ /pubmed/21253449 http://dx.doi.org/10.1155/2011/707542 Text en Copyright © 2011 Francesco Gaudio et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Gaudio, Francesco
Giordano, Annamaria
Pavone, Vincenzo
Perrone, Tommasina
Curci, Paola
Pastore, Domenico
Delia, Mario
de' Risi, Clara
Spina, Alessandro
Liso, Vincenzo
Specchia, Giorgina
Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title_full Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title_fullStr Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title_full_unstemmed Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title_short Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas
title_sort outcome of very late relapse in patients with hodgkin's lymphomas
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023035/
https://www.ncbi.nlm.nih.gov/pubmed/21253449
http://dx.doi.org/10.1155/2011/707542
work_keys_str_mv AT gaudiofrancesco outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT giordanoannamaria outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT pavonevincenzo outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT perronetommasina outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT curcipaola outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT pastoredomenico outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT deliamario outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT derisiclara outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT spinaalessandro outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT lisovincenzo outcomeofverylaterelapseinpatientswithhodgkinslymphomas
AT specchiagiorgina outcomeofverylaterelapseinpatientswithhodgkinslymphomas